MESO | tickerfilter.com

Fundamental analysis

11%

Profitability 0%

Dept financing 7%

Liquidity 27%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.22%

1 Month

54.03%

3 Months

129.38%

6 Months

156.33%

1 Year

695.33%

2 Year

185.57%

Key data

Stock price

$18.20

P/E Ratio

0.00

DAY RANGE

$17.09 - $18.48

EPS

$0.00

52 WEEK RANGE

$1.76 - $19.15

52 WEEK CHANGE

$687.96

MARKET CAP

769.562 M

YIELD

N/A

SHARES OUTSTANDING

114.178 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,275,293

AVERAGE 30 VOLUME

$607,434

Company detail

CEO: Silviu Itescu
Region: US
Website: mesoblast.com
Employees: 80
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Mesoblast Limited offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection. The company has strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd. and Grünenthal.

MESO - MESOBLAST LTD